adminPfizer Inc. (PFE) Jefferies London Healthcare Conference 2025 November 19, 2025 4:00 AM EST
Company Participants
David Denton – Executive VP & CFO
Conference Call Participants
Akash Tewari – Jefferies LLC, Research Division
Presentation
Akash Tewari
Jefferies LLC, Research Division
Good morning, everyone. I hope you’re all doing well. Nice to see a packed room. Day 3 of our London Healthcare Conference. And again, I was mentioning today, it’s good to see optimism and smiling faces year-over-year increase. My name is Akash Tewari. I’m a pharma and biotech analyst here at Jefferies. I have the pleasure of hosting the Pfizer management team. Dave, why don’t I hand it off to you for some entry remarks, and we’ll get started.
Question-and-Answer Session
David Denton
Executive VP & CFO
Great. Thank you. First, thank you for hosting us today. I really appreciate everybody’s interest in the company. I think, as you know, we’re — 2024 and 2025 has been a very interesting and exciting year for us. I think as we started out in this journey for the year, we continue to focus on executing at a high level, both commercially and also financially. We continue to deliver on our financial promises. And importantly, as we think about the next several years, we have a very keen focus on ensuring that we return to growth in the ’29 and ’30 time frame for our business.
Over the next several years, we have many LOEs coming about. So we have done a few things as we begin to manage our way through this LOE period. First and foremost, we’ve improved our cost structure. We’ve identified about $7.7 billion of cost improvements across our business that are being taken out over the next several years. So we’re rightsizing the business for again, as we enter the LOE period, at the same time, making
Read the full article here
